Following were the notable penny stock buzzers in the previous session on high volume. Keep an eye on these stocks this week.
If you are interested in nanocap stocks here is one you should look into
Wearable Health Solutions (OTCMKTS:WHSI) is a manufacturer of next-generation, advanced technology personal medical alarms and safety alert devices. WHSI’s technology can provide a leading edge for the Company in our current cutting-edge technology-driven markets.
● Unique Opportunity
Only Publicly Traded Small-Cap Stock in the $7.4 Billion PERS Market
● Major Marketing Campaign Kickoff Imminent
WHSI is launching a worldwide marketing campaign to expand its international network of distributors. Production is underway for the company’s spots on the weekly ‘Worldwide Business With kathy ireland®” show.
Ireland’s Company Reaches Over 200+ Million Households broadcast on FOX Business Network, Bloomberg International Television and video streams on all major social media platforms.
● iMax 4G Release
WHSI’s iHelp MAX™ 4G device is reportedly launching this year. The device will do more than transmit an emergency alarm for the user. It will also send medical personnel vital signs, such as heart rate.
This next-generation release would be huge for WHSI stock.
● WHSI Up Listing
WHSI’s Mark Cayle recently commented after releasing its Form 10, “Once our Form 10 Registration Statement is effective, we will consider an up listing to a broader stock exchange which could expand our exposure to institutional investors, money managers, family office funds, broker dealers, and other investors which is an important milestone in our corporate progression,” he concluded
An uplisting would be a major catalytic event.
Athersys Inc. (NASDAQ:ATHX) stock was in action in the previous trading session as the stock ended up by 24.56% to $0.3028 with over 14.23 million shares traded hands, compared to its average volume of 4.90 million shares.
Athersys Inc., the Cleveland-based regenerative medicine company, plans to cut its workforce by as much as 70% in a restructuring aimed at reducing costs and making it an attractive investment for potential financial or strategic partners. Athersys has been developing its MultiStem adult stem cell therapy since 1994 and is in late-stage clinical trials with its Japanese partner, Healios K.K., to commercialize the therapy to treat ischemic stroke patients in Japan.
Sesen Bio Inc. (NASDAQ:SESN) stock was one of the notable active movers in previous trading session as the stock ended higher by 20.26% at $0.6821 with over 11.52 million shares traded hands, compared to its average volume of 4.13 million shares.
Sesen Bio, Inc. SESN is a clinical-stage biopharma company working on the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). FDA declined to approve the company’s flagship drug Vicineum. Subsequently, management has started a strategic review.
Trevena Inc. (NASDAQ:TRVN) stock continued to trend higher on Monday. On Monday, the stock gained 4.88% to $0.3736 with more than 3.01 million shares traded hands, compared to its average volume of 1.55 million shares.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine.
Isoray Inc. (NYSE:ISR) stock was one of the most active stock buzzers. The stock ended up by 3.20% at $0.2810 with over 244K shares traded hands, compared to its average volume of 311K shares.
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
Athenex Inc. (NASDAQ:ATNX) stock was in action in the previous trading session as the stock ended up by 7.37% to $0.53 with over 1.53 million shares traded hands, compared to its average volume of 813K shares.
Recently, the company announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the US and Canada). The agreement applies to the expansion phase of the Phase 1 clinical trial evaluating Athenex’s oral paclitaxel in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for certain NSCLC patients.